Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Dig Endosc. 2013 May;25 Suppl 2:2-5. doi: 10.1111/den.12101.
Endoscopic submucosal dissection (SD) has emerged as one of the treatment strategies for submucosal rectal cancers. The present study reviewed the clinical outcomes of patients with rectal submucosal cancer treated by ESD. This was a retrospective review of four patients who had rectal tumor treated by ESD from 2010 to 2012 with histopathology showing T1 submucosal adenocarcinoma. The mean age (SD) was 69.5 (7.33) and the male to female ratio was 3:1. There were no post-ESD complications. The mean (SD) size of the tumors was 2.93 (0.87) cm. One patient with deep resection margin involvement received laparoscopic low anterior resection. Another with deep margin involvement of <1 mm refused surgery and was treated by chemoradiotherapy.There was no recurrence in all the cases with a mean follow-up duration of 461.3 (209.0) days. ESD was one of the important treatment strategies for T1sm-s rectal cancer especially when the risk of nodal metastasis was low. ESD spared the patient from colostomy when the T1 cancer was located in the lower third of the rectum. The role of adjuvant and neoadjuvant chemoradiotherapy remains controversial.
内镜黏膜下剥离术(ESD)已成为治疗黏膜下直肠癌的策略之一。本研究回顾性分析了 2010 年至 2012 年间接受 ESD 治疗的 4 例直肠黏膜下癌患者的临床结局,这些患者的组织病理学均显示 T1 黏膜下腺癌。患者的平均年龄(标准差)为 69.5(7.33)岁,男女比例为 3:1。ESD 后无并发症。肿瘤的平均(标准差)大小为 2.93(0.87)cm。1 例深部切缘受累患者接受腹腔镜低位前切除术,另 1 例深部切缘受累<1mm 患者拒绝手术,接受放化疗。所有患者平均随访 461.3(209.0)天,均无复发。ESD 是 T1sm-s 直肠癌的重要治疗策略之一,尤其是当淋巴结转移风险较低时。当 T1 癌位于直肠下三分之一时,ESD 可避免患者行结肠造口术。辅助和新辅助放化疗的作用仍存在争议。